Oxford Immunotec Global PLC will sell 2.5 million ordinary shares in an underwritten public offering.
The company has granted the underwriter an option to buy up to 375,000 additional shares.
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
BTIG LLC is acting as sole underwriter for the offering.